High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer

Jacobsen,Frank; Ashtiani,Sharad  Nouraie; Tennstedt,Pierre; Heinzer,Hans; Simon,Ronald; Sauter,Guido; Sirma,Hüseyin; Tsourlakis,Maria  Christina; Minner,Sarah; Schlomm,Thorsten; Michl,Uwe

doi:10.3892/etm.2012.764

High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer

Authors:
- Frank Jacobsen
- Sharad Nouraie Ashtiani
- Pierre Tennstedt
- Hans Heinzer
- Ronald Simon
- Guido Sauter
- Hüseyin Sirma
- Maria Christina Tsourlakis
- Sarah Minner
- Thorsten Schlomm
- Uwe Michl
View Affiliations

Affiliations: Institute of Pathology, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany, Martini-Clinic Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany
Published online on: October 25, 2012 https://doi.org/10.3892/etm.2012.764
Pages: 102-106

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

c-MET is considered a possible therapeutic target in numerous tumor types and is also a candidate regulator of response to anti-HER2 and anti-epidermal growth factor receptor (EGFR) therapy. The aim of this study was to determine the prevalence and clinical significance of c-MET expression in hormone-naïve prostate cancers. A pre-existing prostate tissue microarray (TMA) containing samples of 4,177 patients treated by radical prostatectomy was used. A total of 3,378 different prostate cancers were successfully analyzed for c-MET expression by immunohistochemistry and follow-up data were available for 4,104 patients. Membranous c-MET immunostaining was performed for 2,655 (78.6%) tumors. High c-MET protein expression was significantly associated with a high Gleason grade (P=0.0018). However, c-MET was not a prognostic marker for biochemical recurrence. c-MET levels were also not associated with other parameters, including tumor stage, nodal stage and surgical margin status. The c-MET protein is often overexpressed in prostate cancer, but has no prognostic relevance. However, the frequent presence of high levels of membranous c-MET protein in prostate cancer cells makes c-MET an attractive target for imaging and treatment.

View Figures

View References

1	Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 311:29–33. 1984. View Article : Google Scholar : PubMed/NCBI
2	Knudsen BS and Edlund M: Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 91:31–67. 2004. View Article : Google Scholar : PubMed/NCBI
3	Peruzzi B and Bottaro DP: Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 12:3657–3660. 2006. View Article : Google Scholar : PubMed/NCBI
4	Kong DS, Song SY, Kim DH, et al: Prognostic significance of c-Met expression in glioblastomas. Cancer. 115:140–148. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS and Cho MK: Expression of the c-Met proteins in palignant skin cancers. Ann Dermatol. 23:33–38. 2011. View Article : Google Scholar : PubMed/NCBI
6	De Oliveira AT, Matos D, Logullo AF, et al: MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 29:4807–4811. 2009.PubMed/NCBI
7	Matteucci E, Bendinelli P and Desiderio MA: Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis. 30:937–945. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ichimura E, Maeshima A, Nakajima T and Nakamura T: Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res. 87:1063–1069. 1996. View Article : Google Scholar : PubMed/NCBI
9	Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y and Tahara E: Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer. 55:72–75. 1993. View Article : Google Scholar : PubMed/NCBI
10	Belfiore A, Gangemi P, Costantino A, et al: Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab. 82:2322–2328. 1997.PubMed/NCBI
11	Humphrey PA, Zhu X, Zarnegar R, et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 147:386–396. 1995.PubMed/NCBI
12	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
13	Knudsen BS, Gmyrek GA, Inra J, et al: High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 60:1113–1117. 2002. View Article : Google Scholar : PubMed/NCBI
14	Watanabe M, Fukutome K, Kato H, et al: Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett. 141:173–178. 1999. View Article : Google Scholar
15	Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC and Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol. 154:293–298. 1995. View Article : Google Scholar : PubMed/NCBI
16	Tu WH, Zhu C, Clark C, Christensen JG and Sun Z: Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 10:5562010. View Article : Google Scholar : PubMed/NCBI
17	Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ and Gallick GE: The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20:1677–1684. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gross ME, Jo S and Agus DB: Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2:53–56. 642004.PubMed/NCBI
19	Erbersdobler A, Fritz H, Schnöger S, et al: Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol. 41:40–46. 2002. View Article : Google Scholar
20	Bubendorf L: High-throughput microarray technologies: from genomics to clinics. Eur Urol. 40:231–238. 2001. View Article : Google Scholar : PubMed/NCBI
21	Miyamoto M, Ojima H, Iwasaki M, et al: Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 105:131–138. 2011. View Article : Google Scholar : PubMed/NCBI
22	Amemiya H, Menolascino F and Peña A: Role of the expression of c-Met receptor in the progression of gastric cancer. Invest Clin. 51:369–380. 2010.(In Spanish).
23	Freudlsperger C, Alexander D, Reinert S and Hoffmann J: Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med. 1:69–72. 2010.PubMed/NCBI
24	Previdi S, Abbadessa G, Dalò F, France DS and Broggini M: Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther. 11:214–223. 2012. View Article : Google Scholar : PubMed/NCBI
25	Liu X, Wang Q, Yang G, et al: A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 17:7127–7138. 2011. View Article : Google Scholar : PubMed/NCBI